Survival benefit needed to undergo chemotherapy: Patient and physician preferences-Reference-Cited by-同舟云学术

Survival benefit needed to undergo chemotherapy: Patient and physician preferences

Published:2017-03-21 Issue:15 Volume:123 Page:2821-2828
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Vaz-Luis Ines¹^ORCID,O'Neill Anne¹,Sepucha Karen²,Miller Kathy D.³,Baker Emily¹,Dang Chau T.⁴,Northfelt Donald W.⁵,Winer Eric P.¹,Sledge George W.³,Schneider Bryan³,Partridge Ann H.¹

Affiliation:

1. Dana-Farber Cancer Institute; Boston Massachusetts

2. Massachusetts General Hospital; Boston Massachusetts

3. Indiana University Simon Cancer Center; Indianapolis Indiana

4. Memorial Sloan Kettering Cancer Center; New York New York

5. Mayo Clinic; Scottsdale Arizona

Funder

U.S. Public Health Service

National Cancer Institute

Susan G. Komen for the Cure

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30671/fullpdf

Reference22 articles.

1. Decline in the use of anthracyclines for breast cancer;Giordano;J Clin Oncol.,2012

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet.,2012

3. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?;Simes;J Natl Cancer Inst Monogr.,2001

4. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials;Swain;Cancer.,2003

5. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve;Ahles;J Clin Oncol.,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences between physician and patient preferences for cancer treatments: a systematic review;BMC Cancer;2023-11-18

2. Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care;The Oncologist;2023-07-05

3. Patient perspectives on testing for clonal hematopoiesis of indeterminate potential;Blood Advances;2022-12-27

4. Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article;Indian Journal of Surgical Oncology;2022-09-01

5. Addressing the problem of overtreatment in breast cancer;Expert Review of Anticancer Therapy;2022-05-04